Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
Jones, Robin L. , Chawla, Sant P. , Attia, Steven , Schöffski, Patrick , Gelderblom, Hans , Cesne, Axel Le, Patel, Shreyaskumar , Wagner, Andrew J. , Heyburn, John, Weil, Susan C., Viele, Kert , Maki, Robert G. , Maki, Robert G , Jones, Robin L , Gelderblom, Hans , Chmielowski, Bartosz , Tine, Brian A. Van , Trent, Jonathan C. , Chugh, Rashmi , Wang, Wenquan

Mayo Clinic

Cancer | April 30, 2019 | Volume: 125 | Issue: 14 | Pages: 2445-2454

10.1002/cncr.32084 | PMID 31034598 Get It

Background Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM‐1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma. Methods Part 1 was an open‐label, dose‐finding, safety lead‐in: 4, 6, or 8 mg/kg with gemcitabine and docetaxel (G/D; 900 mg/m 2 gemcitabine on days 1 and 8 and 75 mg/m 2 docetaxel on day 8). In part 2, patients were randomized in a double‐blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological cohorts. Results In part 2 with 209 patients, no significant difference in progression‐free survival between ontuxizumab plus G/D (4.3 months; 95% confidence interval [CI], 2.7‐6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6‐8.3 months) was observed ( P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77‐1.49). Similarly, there was no significant difference in median overall survival between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2‐21.1 months) and 21.1 months for the placebo plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82‐1.82). No significant differences between the treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally well tolerated. Conclusions Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft‐tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone.
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy
Lester, Steven J., Owens, Anjali , Wang, Andrew , Lambing, Joseph L., Semigran, Marc J., Sehnert, Amy J. , Wang, Andrew , Heitner, Stephen B. , Jacoby, Daniel Louis , Zhang, David D. , Lee, June

Mayo Clinic

Annals of Internal Medicine | April 30, 2019 | Volume: 170 | Issue: 11 | Pages: 741-748

10.7326/m18-3016 | PMID 31035291 Get It

Association of peripheral artery disease with in‐hospital outcomes after endovascular transcatheter aortic valve replacement
Mohananey, Divyanshu , Villablanca, Pedro , Ando, Tomo , Wang, Dee Dee , Wiley, José , Eng, Marvin H. , Shah, Binita , Saucedo, Jorge , Bhatt, Deepak L. , Ando, Tomo , Wang, Dee Dee , Eng, Marvin , Ramakrishna, Harish , Bhatt, Deepak L , Shah, Binita , Gupta, Tanush , Ranka, Sagar , Bhatia, Nirmanmoh , Adegbala, Oluwole Muyiwa , Kalra, Ankur , O’Neill, William W.

Mayo Clinic

Catheterization and Cardiovascular Interventions | April 26, 2019 | Volume: 94 | Issue: 2 | Pages: 249-255

10.1002/ccd.28310 | PMID 31025488 Get It

AbstractObjectivesThe aim of this study was to determine the prevalence of peripheral artery disease (PAD) and its association with in‐hospital outcomes after endovascular transcatheter aortic valve replacement (EV‐TAVR).BackgroundTAVR is an established treatment for patients at prohibitive, high, or intermediate surgical risk. PAD is a significant comorbidity in the determination of surgical risk. However, data on association of PAD with outcomes after EV‐TAVR are limited.MethodsPatients in the National Inpatient Sample who underwent EV‐TAVR between January 1, 2012 and September 30, 2015 were evaluated. The primary outcome was in‐hospital mortality.ResultsA total of 51,685 patients underwent EV‐TAVR during the study period. Of these, 12,740 (24.6%) had a coexisting diagnosis of PAD. The adjusted odds for in‐hospital mortality [OR 1.08 (95% CI 0.83–1.41)], permanent pacemaker implantation [OR 0.98 (0.85–1.14)], conversion to open aortic valve replacement [OR 1.05 (0.49–2.26)], or acute myocardial infarction [OR 1.31(0.99–1.71)] were not different in patients with versus without PAD. However, patients with PAD had greater adjusted odds of vascular complications [OR 1.80 (1.50–2.16)], major bleeding [OR 1.20 (1.09–1.34)], acute kidney injury (AKI) [OR 1.19 (1.05–1.36)], cardiac complications [aOR 1.21 (1.01–1.44)], and stroke [OR 1.39(1.10–1.75)] compared with patients without PAD. Length of stay (LOS) was significantly longer for patients with PAD [7.23 (0.14) days vs. 7.11 (0.1) days, p < 0.001].ConclusionOf patients undergoing EV‐TAVR, ~25% have coexisting PAD. PAD was not associated with increased risk of in‐hospital mortality but was associated with higher risk of vascular complications, major bleeding, AKI, stroke, cardiac complications, and longer LOS.
Repeatability of linear and nonlinear quantitative compression elastography in the breast
Barbone, Paul E. , Gendin, Daniel , Wang, Yuqi , Nayak, Rohit , Oberai, Assad A. , Hall, Timothy J. , Alizad, Azra , Fatemi, Mostafa

Mayo Clinic

The Journal of the Acoustical Society of America | April 24, 2019 | Volume: 145 | Issue: 3_Supplement | Pages: 1891-1891

10.1121/1.5101854 Get It

Compression elastography allows the precise measurement of large deformations of soft tissue in vivo. From a measured large deformation, an inverse problem for both the linear and nonlinear elastic moduli distributions can be solved. As part of a larger clinical study to evaluate NEMs in breast cancer, we evaluate the repeatability of linear and nonlinear modulus maps from repeat measurements. Within the cohort of 31 subjects scanned to date, several had repeated scans. These repeated scans were processed to evaluate NEM repeatability. In vivo data were acquired by a custom, digitally controlled, uniaxial compression device with force feedback. RF-data were acquired using plane wave imaging, at a frame-rate of 200 Hz, with a ramp-and-hold compressive force of 8N, applied at 8 N/s. A two-dimensional (2D) block-matching algorithm was used to obtain sample-level displacement fields which were then tracked at subsample resolution using 2D cross correlation. Linear and nonlinear elasticity parameters in the Blatz model of tissue elasticity are estimated using iterative optimization. Repeatability between both modes and elastic modulus maps is measured and compared. Preliminary results indicate that when images are acquired in the same region of tissue, the modulus maps are consistent. [Work supported by NIH R01CA195527.]
Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
Athreya, Arjun P. , Neavin, Drew , Skime, Michelle , Frye, Mark A. , Wang, Liewei , Weinshilboum, Richard M. , Biernacka, Joanna, Bobo, William V. , Neavin, Drew R , Carrillo‐Roa, Tania , Biernacka, Joanna M. , Rush, Augustus John , Binder, Elisabeth B. , Iyer, Ravishankar K. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | April 23, 2019 | Volume: 106 | Issue: 4 | Pages: 855-865

10.1002/cpt.1482 | PMID 31012492 Get It

We set out to determine whether machine learning–based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD). We studied 1,030 white outpatients with MDD treated with citalopram/escitalopram in the Mayo Clinic Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN‐AMPS; n = 398), Sequenced Treatment Alternatives to Relieve Depression (STAR*D; n = 467), and International SSRI Pharmacogenomics Consortium (ISPC; n = 165) trials. A genomewide association study for PGRN‐AMPS plasma metabolites associated with SSRI response (serotonin) and baseline MDD severity (kynurenine) identified single nucleotide polymorphisms (SNPs) in DEFB1, ERICH3, AHR, and TSPAN5 that we tested as predictors. Supervised machine‐learning methods trained using SNPs and total baseline depression scores predicted remission and response at 8 weeks with area under the receiver operating curve (AUC) > 0.7 (P < 0.04) in PGRN‐AMPS patients, with comparable prediction accuracies > 69% (P ≤ 0.07) in STAR*D and ISPC. These results demonstrate that machine learning can achieve accurate and, importantly, replicable prediction of SSRI therapy response using total baseline depression severity combined with pharmacogenomic biomarkers.
p300 Acetyltransferase Is a Cytoplasm‐to‐Nucleus Shuttle for SMAD2/3 and TAZ Nuclear Transport in Transforming Growth Factor β–Stimulated Hepatic Stellate Cells
Wang, Yuanguo , Tu, Kangsheng , Liu, Donglian, Maiers, Jessica L. , Liu, Zhikui , Shah, Vijay H. , Tschumperlin, Daniel J. , Voneschen, Luke, Yang, Rendong , Kang, Ningling , Tu, Kangsheng , Shah, Vijay H , Dou, Changwei, Tschumperlin, Daniel, Tu, Kangsheng , Guo, Luyang, Chen, Yun‐Ru , Li, Qing

Mayo Clinic

Hepatology | April 20, 2019 | Volume: 70 | Issue: 4 | Pages: 1409-1423

10.1002/hep.30668 | PMID 31004519 Get It

Nuclear translocation of mothers against decapentaplegic homolog 2/3 (SMAD2/3), core transcription factors of transforming growth factor β (TGF‐β) signaling, is critical for hepatic stellate cell (HSC) differentiation into metastasis‐promoting myofibroblasts. SMAD2/3 have multiple coactivators, including WW domain‐containing transcription regulator protein 1 (WWTR1 or TAZ) and p300 acetyltransferase. In the nucleus, TAZ binds to SMAD2/3 to prevent SMAD2/3 nuclear export. However, how TAZ and SMAD2/3 enter the nucleus remains poorly understood because neither contains a nuclear localization signal (NLS), an amino acid sequence tagging proteins for nuclear transport. p300 is an NLS‐containing large scaffold protein, so we hypothesized that SMAD2/3 and TAZ may undergo nuclear import through complexing with p300. Coimmunoprecipitation, immunofluorescence, and nuclear fractionation assays revealed that TGF‐β1 promoted binding of SMAD2/3 and TAZ to p300 and that p300 inactivation disrupted TGF‐β1‐mediated SMAD2/3 and TAZ nuclear accumulation. Deleting the p300 NLS blocked TGF‐β1‐induced SMAD2/3 and TAZ nuclear transport. Consistently, p300 inactivation suppressed TGF‐β1‐mediated HSC activation and transcription of genes encoding tumor‐promoting factors, such as connective tissue growth factor, Tenascin C, Periostin, platelet‐derived growth factor C, and fibroblast growth factor 2, as revealed by microarray analysis. Chromatin immunoprecipitation‐real‐time quantitative PCR showed that canonical p300‐mediated acetylation of histones also facilitated transcription in response to TGF‐β1 stimulation. Interestingly, although both TGF‐β1‐mediated and stiffness‐mediated HSC activation require p300, comparison of gene expression data sets revealed that transcriptional targets of TGF‐β1 were distinct from those of stiffness‐p300 mechanosignaling. Lastly, in tumor/HSC coinjection and intrasplenic tumor injection models, targeting p300 of activated‐HSC/myofibroblasts by C646, short hairpin RNA, or cre ‐mediated gene disruption reduced tumor and liver metastatic growth in mice. Conclusion: p300 facilitates TGF‐β1‐stimulated HSC activation by both noncanonical (cytoplasm‐to‐nucleus shuttle for SMAD2/3 and TAZ) and canonical (histone acetylation) mechanisms. p300 is an attractive target for inhibiting HSC activation and the prometastatic liver microenvironment.
Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
Schneider, Benjamin , Boyer, Arnaud, Ciccolini, Joseph , Benzekry, Sébastien , Mochel, Jonathan P. , Mochel, Jonathan P , Barlési, Fabrice , Wang, Kenneth

Mayo Clinic

CPT: Pharmacometrics & Systems Pharmacology | April 20, 2019 | Volume: 8 | Issue: 8 | Pages: 577-586

10.1002/psp4.12415 | PMID 31004380 Get It

Bevacizumab‐pemetrexed/cisplatin ( BEV ‐ PEM / CIS ) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM / CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV ‐ PEM / CIS has a narrow therapeutic window. Therefore, it is an attractive target for administration schedule optimization. The present study leverages our previous work on BEV ‐ PEM / CIS pharmacodynamic modeling in non‐small cell lung cancer–bearing mice to estimate the optimal gap in the scheduling of sequential BEV ‐ PEM / CIS . We predicted the optimal gap in BEV ‐ PEM / CIS dosing to be 2.0 days in mice and 1.2 days in humans. Our simulations suggest that the efficacy loss in scheduling BEV ‐ PEM / CIS at too great of a gap is much less than the efficacy loss in scheduling BEV ‐ PEM / CIS at too short of a gap.
Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or diarrhea improvement from corticosteroids or probiotics.
Keefe, Dorothy Mary Kate, Giri, Nagdeep , Reisman, Arlene, Sbar, Eric, Gernhardt, Diana, Jatoi, Aminah , Lacouture, Mario E. , Sonis, Stephen T. , Wang, Tao

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e19049-e19049

10.1200/jco.2015.33.15_suppl.e19049 Get It

Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Perl, Alexander E. , Altman, Jessica K. , Ritchie, Ellen K. , Baer, Maria R. , Litzow, Mark R. , Schiller, Gary J. , Üstün, Celalettin , Gill, Stan, Sargent, Briana, Bahceci, Erkut, Levis, Mark J. , Cortes, Jörge E. , Larson, Richard A. , Smith, Catherine C. , Wang, Eunice S. , Strickland, Stephen Anthony , Claxton, David F. , Liu, Charles Y.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 7003-7003

10.1200/jco.2015.33.15_suppl.7003 Get It